{"entity":{"id":"jennifer-woyach","kind":"person","name":"Jennifer A. Woyach","aka":[],"tldr":"Led Alliance A041202, which showed ibrutinib beats chemoimmunotherapy in older CLL patients, and discovered BTK C481S resistance.","summary":"Jennifer Woyach was principal investigator of Alliance A041202, the trial showing ibrutinib with or without rituximab beats bendamustine-rituximab in older patients with untreated CLL and ending chemoimmunotherapy for this group, and first author of the study identifying BTK C481S and PLCG2 mutations as the mechanisms of ibrutinib resistance. She chairs the Alliance CLL committee and leads trials of fixed-duration combinations.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Woyach%20JA%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"tags":["cll","btk","alliance"],"related":[],"cancers":["cll"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["osu-james"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-amplify-acalabrutinib-venetoclax-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center","institutionId":"osu-james","specialisms":["Chronic lymphocytic leukaemia","BTK inhibitors","Older patients","Resistance mutations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Woyach%20JA%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"papers":[{"title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL (Alliance A041202)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1812836"},{"title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1400029"},{"title":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPLIFY%20acalabrutinib%20venetoclax%20obinutuzumab%20Brown%20NEJM%202025"}]},"route":"/people/jennifer-woyach/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"institution":[{"id":"osu-james","kind":"institution","name":"The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute","route":"/institutions/osu-james/"}],"paper":[{"id":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","kind":"paper","name":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","route":"/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/"}]}}